Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer

Bibliography

• ARMSTRONG DK, SPRIGGS D, LEVIN J, POULIN R, LANE S: Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist (2005) 10(9):686-694.
   PubMed Web of Science ®Google Scholar
• GLAXOSMITHKLINE: Prescribing information: Hycamtin® brand of topotecan hydrochloride for injection (2003).
   Google Scholar
• ARDIZZONI A, HANSEN H, DOMBERNOWSKY P et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a Phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. (1997) 15(5):2090-2096.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, GLISSON BS, LEE JS et al.: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J. Clin. Oncol. (1996) 14(10):2785-2790.
   PubMed Web of Science ®Google Scholar
• VON PAWEL J, SCHILLER JH, SHEPHERD FA et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. (1999) 17(2):658-667.
   PubMed Web of Science ®Google Scholar
• BOOKMAN MA, MALMSTROM H, BOLIS G et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. (1998) 16(10):3345-3352.
   PubMed Web of Science ®Google Scholar
• CREEMERS GJ, BOLIS G, GORE M et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J. Clin. Oncol. (1996) 14(12):3056-3061.
   PubMed Web of Science ®Google Scholar
• MCGUIRE WP, BLESSING JA, BOOKMAN MA, LENTZ SS, DUNTON CJ: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. (2000) 18(5):1062-1067.
   PubMed Web of Science ®Google Scholar
• SWISHER EM, MUTCH DG, RADER JS, ELBENDARY A, HERZOG TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. (1997) 66(3):480-486.
   PubMed Web of Science ®Google Scholar
• TEN BOKKEL HUININK W, GORE M, CARMICHAEL J et al.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. (1997) 15(6):2183-2193.
   PubMed Web of Science ®Google Scholar
• GORDON AN, FLEAGLE JT, GUTHRIE D, PARKIN DE, GORE ME, LACAVE AJ: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2001) 19(14):3312-3322.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG DK: Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. Oncologist (2004) 9(1):33-42.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG D, O’REILLY S: Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist (1998) 3(1):4-10.
   PubMedGoogle Scholar
• OGAWARA M, NEGORO S, NISHIWAKI Y, FUKUOKA M, WATANABE K, NIITANI H: Phase II study of topotecan (TOP) for relapsed small cell lung cancer (SCLC). Lung Cancer (2000) 29(Suppl. 1):40.
   Google Scholar
• GARST J, BULLER R, LANE S, CRAWFORD J: Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin. Lung Cancer (2005) 7(3):190-196.
   PubMed Web of Science ®Google Scholar
• GOLDWASSER F, BUTHAUD X, GROSS M et al.: Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-Cancer Drugs (1999) 10(3):263-265.
   PubMed Web of Science ®Google Scholar
• VON PAWEL J, GATZEMEIER U, PUJOL JL et al.: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J. Clin. Oncol. (2001) 19(6):1743-1749.
   PubMed Web of Science ®Google Scholar
• TREAT J, HUANG CH, LANE SR, LEVIN J: Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist (2004) 9(2):173-181.
   PubMed Web of Science ®Google Scholar
• HERZOG TJ: Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist (2002) 7(Suppl. 5):3-10.
   PubMed Web of Science ®Google Scholar
• MAIN C, BOJKE L, GRIFFIN S et al.: Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technol. Assess. (2006) 10(9):1-148.
   Web of Science ®Google Scholar
• KOSCHEL R, HUBER RM, GATZEMEIER U et al.: Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy. Lung Cancer (2000) 29(Suppl. 1):42.
   Google Scholar
• NIELSEN HA, NIELSEN D, ENGELHOLM SA: Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol. Oncol. (2000) 77(3):383-388.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ M, ROSE PG: Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol. Oncol. (2001) 83(2):257-262.
   PubMed Web of Science ®Google Scholar
• BELINSON J, KENNEDY A, WEBSTER K, KULP B, PETERSON G, MARKMAN M: Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program Phase 2 trial of topotecan (TOPO) administered on a 3-day schedule as salvage therapy of platinum- and paclitaxel-refractory ovarian cancer (ROC). Proc. Am. Soc. Clin. Oncol. (1999) 18:369a. Abstract 1424.
   Web of Science ®Google Scholar
• MORRIS RT: Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. (2003) 90(3 Pt 2):S34-S38.
   PubMed Web of Science ®Google Scholar
• MORRIS R, MUNKARAH A: Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist (2002) 7(Suppl. 5):29-35.
   PubMed Web of Science ®Google Scholar
• GRECO FA, BURRIS HAI, YARDLEY DA, HAINSWORTH JD: Phase II trial of weekly topotecan in the second-line treatment of small cell lung cancer. Lung Cancer (2003) 41(Suppl. 2):237.
   PubMedGoogle Scholar
• HOSKINS P, EISENHAUER E, BEARE S et al.: Randomized Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. (1998) 16(6):2233-2237.
   PubMed Web of Science ®Google Scholar
• HOMESLEY HD, HALL DJ, MARTIN DA et al.: A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol. Oncol. (2001) 83(2):394-399.
   PubMed Web of Science ®Google Scholar
• MORRIS RT, MUNKARAH A, FIELD J, BAKER VV, DRAKE R, MALONE J: Phase II trial of weekly topotecan in patients with potentially platinum sensitive relapsed ovarian and peritoneal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:173b. Abstract 2512.
   Google Scholar
• LEVY T, INBAR M, MENCZER J, GRISARU D, GLEZERMAN M, SAFRA T: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol. Oncol. (2004) 95(3):686-690.
   PubMed Web of Science ®Google Scholar
• ABUSHAHIN F, GRENDYS EC, LURAIN JR, SINGH DK, RADEMAKER AW, SCHINK JC: Weekly topotecan for platinum resistant ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24:653s. Abstract 15040.
   Google Scholar
• SHIPLEY DL, HAINSWORTH JD, SPIGEL DR et al.: Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC) – a Minnie Pearl Cancer Research Network Phase II trial. Proc. Am. Soc. Clin. Oncol. (2006) 24:384s. Abstract 7083.
   Web of Science ®Google Scholar
• ARDIZZONI A, MANEGOLD C, DEBRUYNE C et al.: European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin. Cancer Res. (2003) 9(1):143-150.
   PubMed Web of Science ®Google Scholar
• ECKARDT JR, VON PAWEL J, PAPAI Z et al.: Open-label, multicenter, randomized, Phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J. Clin. Oncol. (2006) 24(13):2044-2051.
   PubMed Web of Science ®Google Scholar
• CHRISTODOULOU C, KALOFONOS HP, BRIASOULIS E et al.: Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a Phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Cancer Chemother. Pharmacol. (2006) 57(2):207-212.
   PubMed Web of Science ®Google Scholar
• FRASCI G, NICOLELLA G, COMELLA P et al.: A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a Phase II study. Br. J. Cancer (2001) 84(9):1166-1171.
   PubMed Web of Science ®Google Scholar
• HOMESLEY H, BENIGNO B, WILLIAMS J, VACCARELLO L: Weekly topotecan combined with weekly paclitaxel in second- or third-line therapy of epithelial ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. (2001) 20:191b. Abstract 2516.
   Google Scholar
• SEHOULI J, SOMMER H, KLARE P et al.: A randomized multicenter Phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24:263s. Abstract 5030.
   Google Scholar
• ZUBKUS JD, HAINSWORTH JD, SPIGEL DR et al.: Topotecan, paclitaxel, and carboplatin in advanced ovarian cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2006) 24:651s. Abstract 15015.
   Google Scholar
• HOCHSTER H, LIEBES L, SPEYER J et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. (1994) 12(3):553-559.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H, WADLER S, RUNOWICZ C et al.: Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. (1999) 17(8):2553-2561.
   PubMed Web of Science ®Google Scholar
• GORE M, RUSTIN G, SCHULLER J et al.: Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer. Br. J. Cancer (2001) 84(8):1043-1046.
   PubMed Web of Science ®Google Scholar
• ROSE PG, GORDON NH, FUSCO N et al.: A Phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol. Oncol. (2000) 78(2):228-234.
   PubMed Web of Science ®Google Scholar
• SCHAEFER PL, MARKS RS, MAHONEY MR et al.: Randomized Phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am. J. Clin. Oncol. (2003) 26(3):236-240.
   PubMed Web of Science ®Google Scholar
• GARST J, HERNDON JE, SHAFMAN T et al.: A Phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clin. Drug Invest. (2006) 26(5):257-266.
   PubMed Web of Science ®Google Scholar
• HUBER RM, RECK M, GOSSE H et al.: Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur. Respir. J. (2006) 27(6):1183-1189.
   PubMed Web of Science ®Google Scholar